Dataset Information

A cross-sectional study to estimate the point prevalence of painful diabetic neuropathy in Eastern Libya.

ABSTRACT:

Background

Painful Diabetic Neuropathy (PDN) is a complication that affects up to one third of people living with diabetes. There is limited data on the prevalence of PDN from countries in the Middle East and North Africa. The aim of this study was to estimate the point prevalence of PDN in adults in Eastern Libya using the self-report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) pain scale.

Methods

We invited patients attending the Benghazi Diabetes Centre who had diabetes for ??5?years to take part in the study. Patients provided consent and completed the Arabic S-LANSS. Anthropometrics, marital status, socioeconomic and education information was recoded and fasting plasma glucose concentration determined.

Results

Four hundred and fifty participants completed the study (age?=?19 to 87?years, BMI?=?17.6 to 44.2?kg/m², 224 women). One hundred and ninety five participants (43.3%) reported pain in their lower limbs in the previous 6?months and 190/195 participants (97.4%) reported a S-LANSS score of ??12 suggesting they had neuropathic pain characteristics. Thus, 42.2% (190/450) of participants with diabetes were categorised as experiencing pain with neuropathic characteristics. Mean ± SD duration of diabetes for participants with PDN (20.4?±?6.5?years) was significantly higher compared with those without PDN (11.1?±?4.6?years). Participants with PDN smoked tobacco for more years than those without pain (7.9?±?12.3?years versus 1.1?±?3.9?years respectively); had significantly higher fasting plasma glucose concentration (143.6?±?29.3?mg/dl versus 120.0?±?17.3?mg/dl) and had a significantly higher levels of education and employment status. The most significant predictors of PDN were duration of diabetes (OR?=?25.85, 95% CI?=?13.56-49.31), followed by smoking for men (OR?=?8.28, 95% CI?=?3.53-9.42), obesity (OR?=?3.96, 95% CI?=?2.25-6.96) and high fasting plasma glucose concentration (OR?=?3.51, 95% CI?=?1.99-6.21).

Conclusion

The prevalence of PDN in people with diabetes in Eastern Libya was 42.2%. Risk factors for developing PDN were high fasting plasma glucose concentration, long duration of diabetes, and higher level of educational and employment status.

SUBMITTER: Garoushi S

PROVIDER: S-EPMC6335782 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A cross-sectional study to estimate the point prevalence of painful diabetic neuropathy in Eastern Libya.

Garoushi Sabri S Johnson Mark I MI Tashani Osama A OA

BMC public health 20190117 1

<h4>Background</h4>Painful Diabetic Neuropathy (PDN) is a complication that affects up to one third of people living with diabetes. There is limited data on the prevalence of PDN from countries in the Middle East and North Africa. The aim of this study was to estimate the point prevalence of PDN in adults in Eastern Libya using the self-report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) pain scale.<h4>Methods</h4>We invited patients attending the Benghazi Diabetes Centre who had ...[more]

PMID: 30654784

Similar Datasets

Project description:IntroductionThis aim of this study was to delineate current clinical scenarios of painful diabetic peripheral neuropathy (PDN) and associated anxiety and depression among patients in Mainland China, and to report current therapy and clinical practices.MethodsA total of 1547 participants were enrolled in the study between 14 June 2018 and 11 November 2019. Recruitment was conducted using a multilevel sampling method. Participants' demographics, medical histories, glucose parameters, Douleur Neuropathique 4 Questionnaire (DN4) scores, visual analogue scale (VAS) pain scores, Patient Health Questionnaire 9 (PHQ-9) scores, Generalised Anxiety Disorder 7 (GAD-7) scores and therapies were recorded.ResultsThe male-to-female ratio was 1.09:1 (807:740), and the mean age at onset was 61.28 ± 11.23 years. The mean DN4 score (± standard deviation) was 4.91 ± 1.88. The frequencies of DN4 sub-item phenotypes were: numbness, 81%; tingling, 68.71%; pins and needles, 62.90%; burning, 53.59%; hypoaesthesia to touch, 50.16%; electronic shocks, 43.31%; hypoaesthesia to pinprick, 37.94%; brushing, 37.82%; painful cold, 29.61%; and itching, 25.86%. Age, diabetic duration, depression history, PHQ-9 score and GAD-7 score were identified as risk factors for VAS pain score. Peripheral artery disease (PAD) was a protective factor for VAS pain score. For all participants currently diagnosed with PDN and for those previously diagnosed PDN, fasting blood glucose (FBG) was a risk factor for VAS; there was no association between FBG and VAS pain score for PDN diagnosed within 3 months prior to recruitment. Utilisation rate of opium therapies among enrolled participants was 0.71% , contradiction of first-line guideline recommendation for pain relief accounted for 9.43% (33/350) and contradiction of second-line guideline recommendation for opium dosage form was 0.57% (2/350).ConclusionModerate to severe neuropathic pain in PDN was identified in 73.11% of participants. Age, diabetic duration, depression history, PHQ-9 score, GAD-7 score and FBG were risk factors for VAS pain scores. PAD was protective factor. The majority of pain relief therapies prescribed were in accordance with guidelines.Trial registrationClinicalTrials.gov identifier, NCT03520608, retrospectively registered, 2018-05-11.

Dataset Information

A cross-sectional study to estimate the point prevalence of painful diabetic neuropathy in Eastern Libya.

Background

Methods

Results

Conclusion

Publications

A cross-sectional study to estimate the point prevalence of painful diabetic neuropathy in Eastern Libya.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets